Effects of intravenous Semelil (ANGIPARS™) on diabetic foot ulcers healing: A multicenter clinical trial

Daru

Volumn 16, Issue SUPPL. 1, 2008, Pages 35-40

  Larijani, B ^a   Heshmat, R ^a,b   Bahrami, A ^c   Delshad, H ^d   Ranjbar Omrani, G ^e   Mohammad, K ^b   Heidarpour, R ^a   Mohajeri Tehrani, M R ^a   Kamali, K ^b   Farhadi, M ^f   Gharibdoust, F ^b   Madani, S H ^g  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Iranian Hospital Dubai   (United Arab Emirates)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g Rabe Rashidi Institute Iran   (Iran)

Author keywords

ANGIPARS ; Diabetes mellitus; Foot ulcer; Semelil; Treatment

Indexed keywords

ANGIPARS; ANTIBIOTIC AGENT; HERBACEOUS AGENT; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SEMELIL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ULCER HEALING; WOUND ASSESSMENT; WOUND CARE; WOUND CLOSURE; WOUND DRESSING; WOUND IRRIGATION;

EID: 38949197101     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. King H, Albert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
2. International Diabetes Federation; Diabetes Atlas 3th edition, 2007
3. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care 1998; 21:2161-77.
4. Palumbo PJ, Melton LJ III. Peripheral vascular disease and diabetes. In: Diabetes in America: diabetes data compiled 1984. Washington, D.C.: Government Printing Office, August 1985: XV-1-XV-21. (NIH publication no. 85-1468.)
5. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. Diabetes Care 1999; 22:1354-60.
6. Larijani B, Forouzandeh F. Diabetic foot disorders. Iran J Diabetes and Lipid Disord 2003; 2(2):103-93
7. U.S. Department of Health and Human Services. Healthy people 2010: Understanding and improving health, vol. 2. Washington, DC: US Government Printing Office, 2000.
8. The diabetic foot optimal prevention and treatment can halve the risk of amputation. Lakartidningen (1999) 96, 37-41.
9. Larijani B, Zahedi M. Diabetic foot: diagnosis and treatment. J. Med. Council. IRI. (1998) 16(3), 193-208.
10. Larijani B, Afshari M, Bastan Hagh MH, Pajouhi M, Baradar Jalili R, Moadi M Prevalence of lower limb amputation in patients with diabetic foot ulcer in Imam Khomeini and Shariati hospitals, 1979-2001 J Med Counc Islam Repub Iran 2005;1(23): 29-25
11. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, Steed DP, Lipkin S. Use of dermagraf, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19:350-4.
12. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21:71-8.
13. Veves A, Falanga V, Armstrong DG, Sabolinski ML. The apligraf diabetic foot ulcer study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24:290-5.
14. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor- BB (becaplermin) in patients with chronic neuropathic diabetic ulcers.Diabetes Care 1998; 21:822-7.
15. Robson M.C. Exogenous growth factor application effect on human wound healing, Progress in Dermatology 30 (1996) 1-7.
16. Larijani B, Hasani Ranjbar S. Overview of diabetic foot; novel treatments in diabetic foot ulcer. DARU 2008; 16(suppl.1): 1-6.
17. Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial. DARU 2008; 16(suppl.1): 25-30.
18. Masoompour SM, Bagheri MH, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer : A phase 2 clinical study. DARU 2008; 16(suppl.1): 31-34.
19. Abdollahi M, Farzamfar B, Salary P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Rodent acute and sub-chronic toxicity evaluation of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing. DARU 2008; 16(suppl.1): 7-14.
20. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky Y.A, Farhadi M. Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. DARU 2008; 16(suppl.1): 15-19.
21. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salary P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™). DARU 2008; 16(suppl.1): 20-24.
22. Van Rijswijk L. Full-thickness leg ulcers: patient demographics and predictors of healing. Multi-Center Leg Ulcer Study Group. J Fam Pract 1993; 36:625-32.
23. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. J Am Acad Dermatol 2000; 43(4):627-30.
24. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003; 26:1879-82.
25. Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol 2000; 142:960-4.
26. Goodson WH, Hunt TK. Studies of wound healing in experimental diabetes mellitus. J Surg Res. 1977; 22(3):221-27.
27. Potemkin V, Aksenov A, Koltsova E. Endocrinology. 1st ed. Moscow (Russia): Mir Publisher; 1989. p. 221-34.
28. Richardson G. Neurogenic disorders. In: Canale ST, Campbell WC, editors. Campbell's operative orthopedics. 9th ed. St. Louis (MO): Mosby Publishing Company; 1998. p. 1813-17.
29. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care. 1998; 21(12):2161-77.
30. Cecil RL, Goldman L, Bennett JC. Cecil textbook of medicine. 20th ed. Philadelphia (PA): WB Saunders Company; 2000 P. 1266-68